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1. Introduction
The safety and utility of dobutamine stress testing are well
established in the evaluation of patients with known or suspected
coronary artery disease [1]. Overall incidence of adverse effects during
dobutamine stress testing is about 5–10%. Transient regional wall
motion abnormalities of left ventricle and hemodynamic effects of
dobutamine infusion during stress testing have been described. Howev-
er, mechanisms and determinants of various ballooning patterns are
unknown.2. Methods and results
This study was a systematic review of all published case studies and
case series from January 2006 to December 2013.We performed a com-
prehensive literature search using keywords— apical ballooning, dobu-
tamine, stress echocardiogram and stress cardiomyopathy, in Medline,
Cumulative Index to Nursing and Allied Health Literature (CINAHL)
and Cochrane database of systematic reviews. Our search yielded a
total of 21 articles of which, 16 were individual case reports and 2
were case series. We compared the baseline characteristics and post
stress testing characteristics of our study patients with thosewith stress
cardiomyopathy from other causes. Statistical analysis was performed
to calculate mean, median and standard deviation for continuous
variables. Categorical variables were expressed as percentages.
The baseline characteristics are summarized in Table 1. Ninety
percent were females with mean age of 65 years. Hypertension was
the most common risk factor and obesity was least common. Approxi-
mately a quarter of study patient had documented psychiatric illness
or stressors. Chest pain or exertional dyspnea was the most common
reason for evaluation with stress testing. The clinical and imaging char-
acteristics of dobutamine induced stress cardiomyopathy are summa-
rized in Table 2. Chest pain or dyspnea was the leading manifestation.
ST segment elevation was common in inferolateral leads. Apical bal-
looning was noted in 95% of the study patients. Recovery rate was 90%
in our analysis and 1 patient died due to sudden cardiac arrest. Time
to recovery varied from 1 day to 3 months. Data regarding recurrence
was available only for 2 patients. Both patients had no recurrence at
one year. Beta blocker was prescribed in over 50% of the patients.http://dx.doi.org/10.1016/j.ijchv.2014.07.005
2214-7632/Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC3. Discussion
Main conclusions of this study are: Demographics and risk factor
proﬁle of patients with dobutamine stress testing (DST) induced tran-
sient cardiomyopathies appear to be very similar to the stress cardiomy-
opathies where dobutamine is not the inciting factor. Study patients are
mostly postmenopausal females with risk factors and clinical presenta-
tion similar to the population with coronary artery disease. However
coronary angiogramwas normal in about three-quarter of the patients.
In general the prognosis was good with complete recovery by about
3 months.
Various mechanisms for wall motion abnormalities have been
postulated, including catecholaminergic excess, focal myocyte injury,
myocardial stunning, and microvascular dysfunction leading to micro-
vascular ischemia, multivessel coronary vasospasm and impaired coro-
nary vasodilatory reserve [3]. Speciﬁcally, the development of severe
systemic hypertension in patients with left ventricular hypertrophy
(LVH), the presence of systolic anterior motion leading to LV outﬂow
tract obstruction (LVOTO) and mitral regurgitation, and mid cavity ob-
struction leading to dynamic intracavity gradients have been postulated
as plausible explanations [4]. However, LVOTOormid cavity obstruction
occurring due to basal hyperkinesis and apical akinesis, increased re-
sponse of the apex to adrenergic stimulation reﬂecting a differential
beta receptor distribution, base-to-apex perfusion gradient cannot ex-
plain mid-ventricular ballooning pattern [5,6]. Transient cardiomyopa-
thy during dobutamine infusion is commonly noted at peak doses
ranging from 20 to 50 mcg/kg/min, in some instances, it can develop
during recovery. Hence imaging during recovery is as important as
obtaining baseline and peak dobutamine infusion images [7]. Signiﬁ-
cance of atropine administration in this setting is due to lack of data.
Parasympathetic withdrawal after atropine administration, creating an
imbalance between the parasympathetic and sympathetic inﬂuence, is
thought to be contributory. In addition, inhalational beta-agonists,
centrally acting stimulants such as methylphenidate can contribute to
exaggerated sympathetic activity. It is also speculated that such
catecholamine-induced myocyte injury is focal, leading to edema and
necrosis in the acute phase. This may lead to late gadolinium enhance-
ment (LGE) in the acute phase, but in the healing phase, necrotic areas
are replaced by microscars with size below voxel resolution and mag-
netic resonance imaging (MRI) threshold for detection of ﬁbrous scar
[8]. Strain imaging/strain rate curve analysis in patients with stress car-
diomyopathy has shown reduced systolic peak and postsystolic thick-
ening in the affected segments.
Recurrence has mostly been associated with pheochromocytoma
but isolated cases with no identiﬁable triggers have been reported.
While there have been reports of Takotsubo cardiomyopathy affecting
different LV walls with each recurrence [9], such cases would be rare
with dobutamine as it would be difﬁcult to re-challenge such patients.
Supportivemedical treatment, when instituted in a timely fashion, is
lifesaving. In addition to beta-blocker, rehydration and afterload
augmentation with phenylephrine are recommended in those with-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline characteristics.
Variable Study
population
Stress cardiomyopathy
from other causes [2]
Mean age (standard deviation) in years
All 64.7 (12.4) 69 (12)
Male 63 (14) 70 (10)
Female 64.8 (12.7) 69 (12)
Females (%) 19 (90%) 89%
Males (%) 2 (10%) 11%
Cardiovascular risk factors (%) 18 (86%)
Hypertension 12 (57%) 73%
Hyperlipidemia 5 (24%) 26%
Diabetes mellitus 3 (14%) 19%
Smoking 6 (29%) 20%
Obesity 1 (5%) 19%
Others — family Hx, COPD, PVD, CKD 4 (19%) –
Psychiatric illness (%) 5 (24%) 30%
Emotional stressors 1 (5%) 30%
Reason for dobutamine testing (%)
Chest pain or exertional dyspnea 15 (71%)
Pre-operative cardiac testing 2 (10%)
Others 3 (14%)
Baseline electrocardiogram abnormality (%) 4 (19%) –
Baseline left ventricular ejection fraction Normal 47%
COPD — chronic obstructive airway disease, PVD — peripheral vascular disease,
CKD — Chronic kidney disease.
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converting enzyme inhibitors, nitroglycerin, and statins have been pre-
scribed to improve endothelial dysfunction andmicrovascular coronary
vasospasm. In patients with cardiogenic shock, treatment is mainly
supportive with intra-aortic balloon pump. Levosimendan is a calcium
sensitizer and a non-catecholamine inotrope which has been used suc-
cessfully in cardiogenic shock related to stress cardiomyopathy [10].
We acknowledge the limitations in our study. First, the descriptive
nature and retrospective design of the study prevent us from establish-
ing causal relationships. Nevertheless, the results of this study will en-
able us to propose hypotheses for the future studies. Second, the study
had a relatively small sample size, probably due to rarity and under
reporting of cases. This small sample size and rarity of fatal outcomes
precluded us from performing statistical analysis to predict risk factors
for poor outcomes and determine statistical differences between con-
trol and study groups. Third, the source of data was from publishedTable 2
Clinical manifestations, troponin elevation and imaging characteristics after dobutamine
infusion.
Variable Study
population
Stress cardiomyopathy
from other causes [2]
Clinical manifestations (%)
Chest pain or dyspnea 19 (90%) 88%
Hypotension 2 (10%) –
Others — palpitations, back pain 2 (10%) –
Elevated troponin (%) 11 (85%) 90%
Median (ng/ml) 2.56 0.4
Interquartile range (ng/ml) 0.73–5.65 0.1–1.0
ST elevation in stress electrocardiogram (%) 15 (71%) 42%
Inferolateral leads 11 (52%) –
Anterior leads 8 (38%) –
No electrocardiographic changes 4 (19%) 13%
Ballooning pattern (%)
Apical 20 (95%) 82%
Basal 1 (5%) 1%
Midventricular 4 (19%) 17%
Biventricular – 34%
LV thrombus (%) – 2%
Coronary angiogram (%)
Normal 16 (76%) 75%
Non obstructive 5 (24%) 24%
Vasospasm – 2%manuscripts and some reports had incomplete data sets. Lastly, long
term follow-up was available only in minority of patients.
4. Conclusion
In summary, the demographic, clinical and imaging proﬁles of
transient cardiomyopathy from DST are comparable to classical stress
cardiomyopathy. Complete recovery is expected in short term but pro-
spective studies are needed to assess long term outcomes. Additional
mechanisms such as intracavity gradients in patients with signiﬁcant
LVH, imbalance between parasympathetic and sympathetic stimulation
fromatropine administrationmay play a role. Alternative tests for ische-
mia workup should be considered in susceptible patients.
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